Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vyvgart

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

Argenx stock surged Wednesday after Amgen presented "underwhelming" results for a potential competitor to Vyvgart in an autoimmune disease.

Investors Business Daily

New S&P 500 Entrant Airbnb And DKNG Lead 5 Stocks Near Buy Points

New S&P 500 Entrant Airbnb And DKNG Lead 5 Stocks Near Buy Points

Airbnb, which is set to join the S&P 500 on Monday, and DKNG lead a watch list of stocks poised to make moves if the stock market can find its footing.

Investors Business Daily

How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug

How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug

Argenx is Friday's IBD Stock Of The Day. The biotech stock is climbing the right side of a cup base on enthusiasm for its drug, Vyvgart.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market

AI stock standout Arista Networks and Netherlands-based biotech Argenx lead this weekend's watch list of 5 stocks holding in or near buy range.

Investors Business Daily

Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

Argenx is up around 40% in 2023. On Thursday, the company reported second-quarter revenue ballooning 230% as sales of its lone product ramp up.

Investors Business Daily

SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space

SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study

Argenx SE's (NASDAQ:ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint. The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP. Patients were heavily pretreated. A higher proportion of patients with chronic ITP receiving VYVGART (17/78; 21.8%) than placebo…

inkl

Read news from The Economist, FT, and more,
with one subscription

Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores

Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores

Argenx SE (NASDAQ: ARGX) announced

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ: ARGX) ) has

People

King Charles III

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

British Airways

Arista Networks

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Autoimmune Disease

Places

256,061 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play